Public procurement notice: Contract Notice
Published: 2019-10-07
Buyer: The NHS Commissioning Board (operating Under the name of NHS England)
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 987906001 GBP
Submission deadline: 2019-11-07
Award criteria: The most economic tender

Technical requirements: NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux
NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux.
CM/PHR/16/5527/01 — Tranche B: 1.3.2020 to 28.2.2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1.3.2020 to 28.2.2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, South of England – 1.3.2020 – 31.8.2020, Midlands and East – 1.3.2020 – 28.2.2021, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/16/5527/01 — 1.3.2020 to 28.2.2022 – NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other Monoclonal Antibodies
CM/PHR/16/5527/02 – 1.3.2020 to 28.2.2021 — NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — cytokine modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
South of England – 1.3.2020 – 31.8.2020, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
Midlands and East – 1.3.2020 – 28.2.2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
Responding to this notice. Any supplier may be disqualified who does not respond to the following in the requisite manner:
1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at: www.nhsengland.bravosolution.co.uk
Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:
1.1) If not already registered, candidates should register on the eTendering portal at: https://www.nhsengland.bravosolution.co.uk and click the link to register:


Award value: 987906001